Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Arovella Therapeutics Limited ( (AU:ALA) ) is now available.
Arovella Therapeutics Limited has issued 3,043,478 ordinary shares without disclosure under the Corporations Act, in compliance with relevant legal provisions. This issuance supports the company’s strategic focus on advancing its iNKT cell therapy platform and expanding its reach in cancer treatment, potentially enhancing its market position and offering new opportunities for stakeholders.
More about Arovella Therapeutics Limited
Arovella Therapeutics Ltd is a biotechnology company that specializes in developing invariant natural killer T (iNKT) cell therapy platforms to treat blood cancers and solid tumors. Their lead product, ALA-101, involves CAR19-iNKT cells targeting CD19, an antigen found on various cancer types. The company is also working on solid tumor treatments using CLDN18.2-targeting technology and IL-12-TM technology.
Average Trading Volume: 1,786,666
Technical Sentiment Signal: Sell
Current Market Cap: A$106.2M
For detailed information about ALA stock, go to TipRanks’ Stock Analysis page.